U.S. Markets closed

Amicus Therapeutics, Inc. (FOLD)


NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
13.74-0.01 (-0.07%)
At close: 4:00PM EDT

13.74 0.00 (0.00%)
After hours: 5:09PM EDT

People also watch
ACHNTGTXHALOARRYMACK
  • Bill, you digress. galafold is unnecessary, there is a therapy available that addresses the larger population vs the limited population with galafold! duh

    As we wait for Crowley to unleash the EB results, which I highly doubt are good enough to register, thus the secondary offering before results as opposed to after (this quarter right Crowley, or is there ANOTHER delay/defer?)!
  • What were Galafold sales last quarter??? 4 Million (grew over 30% from 2.8 million in the first quarter 2017, lol)

    How much did they spend to earn those sales dollars? 19 Million?
  • Since mathspew and moeron ignore my thoughts on them wishing failure to life saving drugs, I figured I would post one more time to see if they can defend themselves. I expect the "well if Crowley is a crook" like response or "it's about making money". Either way they are pfaggots with no sense of decent morality.
  • I have one question for the irrational here!

    Why would you issue stock here (13 bucks) right before you get great news (and the stock goes super high) on the phase 3 data for EB????

    Crowley is wicked smart...or just plain wicked...
  • KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension
    https://baystreet.ca/articles/research_reports/lifesci/Kitov062717.pdf

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

    Products

    Kitov’s current pipeline products, KIT-301 and KIT-302, are combination drugs that treat OA pain and HTN simultaneously. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its Phase III clinical trial. In August 2016, the United States Patent Office issued a patent covering KIT-302.

    Market

    Of the 27 million Americans with OA, 50% also suffer from HTN, which is also a common side effect of stand-alone OA drugs. With no single medication currently treating both conditions, KIT-301 and KIT-302 are targeting this multi-billion dollar market.

  • Longs, Beware the prescient posts of moe. He has been so spot on since his bashing of FOLD at 6 bucks that when he says our CEO is a #$%$, he must have information that points to that. He says that Mr. Crowley lied about the FDA requiring a new trial for Migalistat as the FDA NEVER does stuff like that. CEOs of BMY, LLY, MRK ect have all had that happen to them but what would they know about the FDA? Hell just because they run billion dollar companies doesn't mean that they too aren't liars when the FDA coldcocks them out of nowhere. moeRon also won't post his position here so we must suspect that his bashing of FOLD, which began at 5 dollars or so, is his original short price. He will say it doesn't matter if one makes money and that I focus on it too much. His arguement is nothing but liberal spew that is intended to distract from the fact that he is getting killed here. It's s easy for people like moeRon to bash behind her keyboard. What a pfaggot.
  • mathew is a compulsive liar and and the vice president of the imbecile section of the moron club. He hates FOLD because he worked as a janitor at their HQ and he got caught backhanding himself to kiddie porn so they fired him. hahahahaaha
  • Hey mathew whats it like to be down 120%? Think how much you would have if only you listened to me. hahahahahahahaha
  • As Crowley prepares to deliver...look out BELOW!
  • Day after secondary announcement the stock craters ( 7/13) & in the following 5 days quickly recovers & rises 14% ...wow!.... secondary offerings are usually more toxic...huge sign of strength ...stay long my friends...this is the real deal.
  • 12.50 or gap needs filled at 11.50? Typical chat move for these spikes.
  • You better cover. Back under 13.
  • So you get great news and offer up a stock offering. Seems pretty smart in that you would have expected a rebound since the money was geared to bring the drug to market. Maybe I'm wrong but why not do that while stock is high and protect the funds needed. I can only hope that confidence level is one combing from a great comfort in the success of this drug.
  • Hey moe, Who's making the money here? hahahahahahahahahaahaa
  • This is one of the best price actions I've seen after the offering. Company raised $250m and price recovered basically to the 7/12 point
  • Harry Boxer has posted his Tuesday’s Charts of the Day video on FOLD at TheTechTrader site noting: Swing trade Amicus Therapeutics, Inc. (FOLD) is acting great, popping another 90 cents, or 7%, to 13.81, on 7.85 million shares traded. That’s heavy volume for this stock. It popped, consolidated, and exploded, pulled back, held the gap, ran up and pulled back again, and then ran up again on Tuesday. I’m looking for 15 and 18 as targets going forward.
  • I think Amicus raised money in anticipation of the results from Zorblisa Phase 3 study which will be released any time this quarter. If the results are positive, Amicus will need to pay substantial clinical and regulatory milestones to Scioderm shareholders. Here is quote from Scioderm acquisition PR:
    "Amicus has agreed to pay up to an additional $361 million to Scioderm shareholders, option holders and warrant holders upon achievement of certain clinical and regulatory milestones."
  • Harry Boxer has posted his Charts of the Day video on FOLD at TheTechTrader site noting: Amicus Therapeutics, Inc. (FOLD) popped out of the wedge and pulled back, and was up just 7 cents to 12.91, on 8 million shares traded. I wanted you to see this pattern as it portends more upside to 15 and 18.
  • Why would FOLD need to raise cash? They have pleny
  • We should all be wise to remember that this company is burning through cash at a rate of 50+ million PER quarter and will make less than 50 million in revenue this year.